Fundraising Fox
Promis Diagnostics, Inc
1 known investors
Find your way into Promis Diagnostics, Inc
Sign up to see every warm intro you have to Promis Diagnostics, Inc
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Promis Diagnostics, Inc team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Promis Diagnostics develops noninvasive tests for early detection of colorectal, bladder, and lung cancer using its patented LTE-qMSP technology, which uses methylated DNA as biomarkers via PCR. The company targets patients seeking accessible and affordable cancer screening options.
Investors · 1
Related companies · 6
MIRA DX, Inc.MiraDx develops genetic biomarker tests, such as PREVIOTOX and PROSTOX Ultra, that help physicians assess cancer patients' risk of treatment-related toxicity and response to therapies like immunotherapy and radiation. The company applies novel biomarkers, including the inherited KRAS-variant, to support more personalized cancer care decisions.
CareDxCareDx provides innovative solutions and diagnostic tools for transplant patients throughout their pre- and post-transplant journey to improve outcomes and equity in organ transplantation.
MDxHealthMDxHealth is a commercial-stage precision diagnostics company offering molecular diagnostic tests to guide the diagnosis and treatment of prostate cancer and other urologic diseases. Its tests use proprietary genetic, epigenetic, and molecular technologies and serve physicians, patients, payers, and providers.
Foresight DiagnosticsForesight Diagnostics develops ultra-sensitive molecular diagnostic tests that combine genomics and bioinformatics to detect minimal residual disease and circulating tumor DNA across multiple cancer types. Its offerings support oncology drug development, clinical trials, and patient care for academic and biopharma partners.
Pink DxPinkDx is a diagnostics company developing tests, led by a leadership team spanning scientific, medical, and business functions.
EarlydxEarlyDx develops non-invasive liquid biopsy tests aimed at early cancer detection and precision medicine. The company positions its tests as accurate and affordable diagnostics.
Companies working in the same space as Promis Diagnostics, Inc.
Frequently asked questions
- What does Promis Diagnostics, Inc do?
- Promis Diagnostics develops noninvasive tests for early detection of colorectal, bladder, and lung cancer using its patented LTE-qMSP technology, which uses methylated DNA as biomarkers via PCR. The company targets patients seeking accessible and affordable cancer screening options.
- Who are Promis Diagnostics, Inc's investors?
- Promis Diagnostics, Inc's investors include Solidus Investment.